News
Merck: In related studies, the use of KEYTRUDA in combination with PADCEV reduced the risk of death in bladder cancer patients by 50% and the risk of recurrence and metastasis events by 60%
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments